Literature DB >> 18048966

Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma.

Daniel G Weber1, Dirk Taeger, Beate Pesch, Thomas Kraus, Thomas Brüning, Georg Johnen.   

Abstract

SMRP (soluble mesothelin-related peptides) is a promising marker for detection of malignant mesotheliomas (MM) in serum that has not yet been validated in appropriate epidemiological studies. Field studies might not always provide optimal conditions for storage and transport of samples, and follow-up studies have to rely on sample integrity. Proper validation of the marker would require sufficient stability of the antigen and robustness of the assay. SMRP concentrations were evaluated in serum samples of 98 healthy donors, using the MESOMARK ELISA kit. The SMRP distribution in the healthy study population was determined and biological and pre-analytical variations were examined regarding their influence on SMRP concentrations. For diagnostic decisions a best statistical and unbiased cut-off between 1.5 and 1.6 nmol/L was determined (95th percentile). No age- or gender-specific differences could be observed. SMRP exhibits excellent stability regarding short-term storage, long-term storage, and repeated freeze/thaw cycles. Scientific studies as well as real life applications that employ SMRP would not be limited by sample stability issues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18048966     DOI: 10.3233/cbm-2007-3602

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  11 in total

1.  Individual predictors of increased serum mesothelin in asbestos-exposed workers.

Authors:  Rosa Filiberti; Paola Marroni; Manlio Mencoboni; Virginia Mortara; Pietro Caruso; Alex Cioè; Luigi Michelazzi; Domenico F Merlo; Andrea Bruzzone; Barbara Bobbio; Lisette Del Corso; Roberto Galli; Paola Taveggia; Guglielmo Dini; Fabio Spigno
Journal:  Med Oncol       Date:  2013-01-01       Impact factor: 3.064

2.  Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum.

Authors:  Daniel Gilbert Weber; Georg Johnen; Dirk Taeger; Anne Weber; Isabelle Mercedes Gross; Beate Pesch; Thomas Kraus; Thomas Brüning; Monika Gube
Journal:  Biomark Insights       Date:  2010-01-28

3.  Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients.

Authors:  Irina Raiko; Ingrid Sander; Daniel G Weber; Monika Raulf-Heimsoth; Adrian Gillissen; Jens Kollmeier; Arnaud Scherpereel; Thomas Brüning; Georg Johnen
Journal:  BMC Cancer       Date:  2010-05-28       Impact factor: 4.430

4.  Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma.

Authors:  Kazuya Fukuoka; Kozo Kuribayashi; Shusai Yamada; Kunihiro Tamura; Chiharu Tabata; Takashi Nakano
Journal:  Mol Clin Oncol       Date:  2013-09-02

5.  Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis.

Authors:  Daniel G Weber; Swaantje Casjens; Georg Johnen; Oleksandr Bryk; Irina Raiko; Beate Pesch; Jens Kollmeier; Torsten T Bauer; Thomas Brüning
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

6.  Calretinin as a blood-based biomarker for mesothelioma.

Authors:  Georg Johnen; Katarzyna Gawrych; Irina Raiko; Swaantje Casjens; Beate Pesch; Daniel G Weber; Dirk Taeger; Martin Lehnert; Jens Kollmeier; Torsten Bauer; Arthur W Musk; Bruce W S Robinson; Thomas Brüning; Jenette Creaney
Journal:  BMC Cancer       Date:  2017-05-30       Impact factor: 4.430

7.  Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies.

Authors:  Daniel G Weber; Swaantje Casjens; Alexander Brik; Irina Raiko; Martin Lehnert; Dirk Taeger; Jan Gleichenhagen; Jens Kollmeier; Torsten T Bauer; Thomas Brüning; Georg Johnen
Journal:  Biomark Res       Date:  2020-05-13

8.  Re-evaluation of potential predictors of calretinin and mesothelin in a population-based cohort study using assays for the routine application in clinical medicine.

Authors:  Swaantje Casjens; Georg Johnen; Irina Raiko; Beate Pesch; Dirk Taeger; Carmen Töpfer; Sandra Schonefeld; Susanne Moebus; Karl-Heinz Jöckel; Thomas Brüning; Daniel Weber
Journal:  BMJ Open       Date:  2021-02-18       Impact factor: 2.692

9.  Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study.

Authors:  Swaantje Casjens; Daniel G Weber; Georg Johnen; Irina Raiko; Dirk Taeger; Carmen Meinig; Susanne Moebus; Karl-Heinz Jöckel; Thomas Brüning; Beate Pesch
Journal:  BMJ Open       Date:  2017-10-11       Impact factor: 2.692

10.  Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.

Authors:  Georg Johnen; Katarzyna Burek; Irina Raiko; Katharina Wichert; Beate Pesch; Daniel G Weber; Martin Lehnert; Swaantje Casjens; Olaf Hagemeyer; Dirk Taeger; Thomas Brüning
Journal:  Sci Rep       Date:  2018-09-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.